Revance Therapeutics Provides Update On RT001 Clinical Program For The Lead Indication For Crow's Feet Lines

Revance Therapeutics, Inc. RVNC, a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company has initiated a study to confirm this quarter the successful transfer of production of the topical RT001 drug product to Revance's U.S. commercial manufacturing facility. Following successful confirmation of this transfer, Revance plans to initiate its first U.S. Phase 3 RT001 pivotal study for the treatment of lateral canthal (crow's feet) lines, with results now anticipated during the first quarter of 2015. Previously, Revance expected to report results from the first U.S. Phase 3 pivotal study by the end of 2014. "To confirm success of the production transfer, we decided to initiate an open-label clinical study using RT001 drug product made in our commercial manufacturing facility," said Dan Browne, Revance's President & CEO. "We believe taking the extra time to complete this short duration clinical study to confirm successful manufacturing transfer of RT001 prior to enrolling patients in our Phase 3 pivotal studies has the potential to benefit our pipeline of RT001 product candidates." "The recently initiated open-label study is a four-week, multi-center study of up to 60 patients. We plan to provide a clinical program update on both of our product candidates, topical RT001 and injectable RT002, during our third quarter earnings conference call in November," added Browne.